Sunday, March 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Dr. Samant Virk, founder of MediSprout

Dr. Virk is a Neurologist trained in interventional spine and pain management who founded the startup, MediSprout.

MediSprout connects doctors with their patients using secure two-way video through a platform that can be downloaded onto a smart device or desktop. It promotes continuity of care by keeping doctors and patients better connected between visits, providing an easy way to refill prescriptions, review test results, ask questions or simply check in on a care plan.

To collaborate with MediSprout, select the following link.

For further questions about signing up, or just to learn more about MediSprout, please email: [email protected]

For a select list of Dr. Virk’s writings, please select the articles below:

MediSprout Archives

KevinMD Archives

Will remote patient monitoring be a lifeline or a liability?

There’s no patient-centered care without patient-centered data

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!